Ataxia-Telangiectasia Grants
This grant provides funding for researchers and organizations to develop innovative treatments and interventions for ataxia telangiectasia, focusing on projects with a clear path to clinical application.
The A-T Children’s Project offers translational and clinical research grants specifically focused on projects related to ataxia-telangiectasia (A-T). Grants are available for a duration of one or two years, with a maximum total direct cost funding of $75,000 per year. It is a strict requirement that 100 percent of the awarded funds be allocated exclusively to direct project costs. Administrative, overhead, or indirect costs are not allowed to be covered by the grant funds, as the organization is committed to donors to ensure direct impact from their contributions. Grant decisions are made through a two-tiered, peer-review selection process. Applications are reviewed on a rolling basis, and decisions are typically communicated to applicants within 90 days of submission, allowing for a relatively fast turnaround compared to many other grant-making organizations. Before submitting a full proposal, applicants must first submit a Letter of Intent (LOI) as a PDF to grants@atcp.org. If invited, the applicant can then submit a full proposal, also in PDF format. The A-T Children’s Project emphasizes funding for projects that are likely to lead to translational advances or clinical interventions. Their guidelines specify particular areas of interest and offer candid advice on proposal success, though these details must be accessed separately through their website’s guideline documents. Applicants are also encouraged to contact the organization for assistance in forming collaborations or accessing research reagents relevant to A-T or ATM research. For inquiries, the A-T Children’s Project can be reached at +1 954-481-6611 or via email at grants@atcp.org. The physical office addresses are 6810 N. State Road 7, Suite 125, Coconut Creek, FL 33073 USA, and 255 Main Street, Eighth Floor, Cambridge, MA 02142 USA. While no specific application deadline was provided, the rolling basis for application acceptance suggests ongoing opportunities throughout the year. Similarly, there is no stated award announcement date, though decisions are made within approximately 90 days of submission.
Award Range
Not specified - $75,000
Total Program Funding
Not specified
Number of Awards
Not specified
Matching Requirement
No
Additional Details
Funding is exclusively for direct costs related to A-T projects; administrative, overhead, or indirect costs are not covered.
Eligible Applicants
Additional Requirements
- Eligible applicants include academia and industry scientists, small biotechnology and large pharmaceutical companies, and venture capital firms incubating new technologies related to ataxia telangiectasia (A-T). - The grants support basic, translational, and clinical research. - Creative ideas from investigators are welcome. - Projects addressing specific gaps in scientific understanding, patient need, or therapeutic development are encouraged. - Supplemental funding may be provided for grants showing significant progress and continued potential. - Grants come with additional support such as access to research tools, guidance from experienced advisors, and networking opportunities. - The current focus is on projects that have a clear path to a treatment or intervention for A-T, including DNA-based modalities, testing compounds with strong mechanistic hypotheses, biomarker development, and digital tools for clinical development. - One and two-year projects are funded up to a maximum total direct cost of $75,000 per year. - Junior investigators are encouraged to apply. - Grant decisions are made through a two-tiered peer-review selection process within 90 days of receiving a complete proposal. - Funding priorities include translational and clinical research focused on neurological problems faced by A-T patients. - Disease-modifying strategies and symptom-improving strategies related to neural circuit function, immune system health, lung function, and especially neurological symptoms are of interest. - Earlier-stage discovery research may be supported if it reveals a path to new treatments or produces tools/resources for treatment development. - Research on the role of the ATM protein in cancer or strategies for treating cancer in A-T patients is unlikely to be funded. - Popular methodologies or favorite areas of focus that require a stretch of imagination for relevance to A-T may not be supported. - Funding must be used solely for the direct costs of the A-T-related project without covering administrative or overhead costs. - Research must begin within six months of the grant start date; failure to start may result in grant termination. - Progress reports must be submitted every six months. - Equipment funding
Geographic Eligibility
All
Application Opens
Not specified
Application Closes
Not specified
Subscribe to view contact details